HomeAI · summaries
Storia in 2 fonti
MOFSL stays bullish on Sun Pharma; sees 16% upside on innovation pipeline
Sun Pharma's June quarter results met analyst expectations, signaling future growth. The company is expanding its specialty and innovative medicines portfolio significantly. Strategic initiatives like semaglutide launches and the Organon acquisition are key drivers. Despite US generics pressure, domestic business and specialty products show strong momentum. Analysts maintain a positive outlook, anticipating substantial growth from these ventures.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Sun Pharma Q1 Results: Profit rises 27% YoY to Rs 2,895 crore; revenue climbs 10.5%
Sun Pharma Q1 Results: Sun Pharma reported a 27% YoY rise in Q1 net profit to Rs 2,895 crore, while revenue grew 10% to Rs 15,300 crore, driven by strong performance in India and…
- ·
thehindu.com
Sun Pharma Q1 net rises 27% to ₹2,895 crore
Sun Pharmaceuticals Industries Ltd. for the first quarter ended June 30, 2026 reported a 27% year-n-year growth in consolidated net profit to ₹2,895 crore.
